Uncategorized

Clearside Biomedical, Inc. Announces Positive Topline Data from Phase 2 Clinical Trial for the Treatment of Macular Edema Associated with Non-Infectious Uveitis

by Business Wire • 2016/01/05 • 0 Comments

ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, a clinical-stage biopharmaceutical company developing drugs for the eye, announces positive Phase 2 trial topline data for macular edema associated with non-infectious uveitis.

← Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer

Allegro Ophthalmics Announces Last Patient Enrolled in DEL MAR Phase 2b Clinical Trial of Luminate® for the Treatment of Diabetic Macular Edema →

Post navigation